Table 2.
Histopathological and Therapeutic Characteristics Among BC Patients in Placebo (n = 23) and Intervention (n = 23) Groups at Baseline of Studya.
| Characteristics | LO (Placebo) | HO (Intervention) | P Value |
|---|---|---|---|
| Menopausal status | |||
| Premenopausal | 19 (82.6)b | 17 (73.9) | |
| Postmenopausal | 4 (17.4) | 6 (26.1) | .722c |
| Tumor size (cm) | |||
| Mean ± SD | 3.5 ± 1.4 | 3.3 ± 1.5 | .527d |
| ≤2 | 4 (18.2)b | 5 (22.7)b | |
| 2.1-5.0 | 15 (68.2) | 14 (63.6) | |
| >5 | 3 (13.6) | 3 (13.6) | .930 |
| Nuclear grade | |||
| 1 or 2 | 19 (86.4) | 20 (90.9) | |
| 3 | 3 (13.6) | 2 (9.1) | 1.000c |
| ER | |||
| Negative | 2 (9.1) | 1 (4.5) | |
| Positive | 20 (90.9) | 21 (95.5) | .550c |
| PR | |||
| Negative | 2 (9.1) | 0 (0.0) | |
| Positive | 20 (90.9) | 22 (100.0) | .488c |
| Surgery | |||
| Breast conservation | 4 (17.4) | 2 (8.7) | |
| Mastectomy | 19 (82.6) | 21 (91.3) | .655c |
| Adjuvant endocrine therapy | |||
| No | 6 (27.3) | 7 (31.8) | |
| Tamoxifen | 14 (63.6) | 9 (40.9) | |
| Letrozole | 2 (9.1) | 6 (27.3) | .256 |
| Lymphatic invasion | |||
| Yes | 10 (45.5) | 8 (36.4) | |
| No | 12 (54.5) | 14 (63.6) | .540 |
Abbreviations: BC, breast cancer; LO, low onion group (placebo); HO, high onion group (intervention); ER, estrogen receptor; PR, progesterone receptor.aSome missing data exit in variables.bData are expressed as observed number (%).cFisher exact test was considered.dIndependent sample t test was performed.